MedPath
FDA Approval

Lisinopril and Hydrochlorothiazide

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
May 10, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Lisinopril(10 mg in 1 1)
Hydrochlorothiazide(12.5 mg in 1 1)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

PD-Rx Pharmaceuticals, Inc.

156893695

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

PD-Rx Pharmaceuticals, Inc.

PD-Rx Pharmaceuticals, Inc.

PD-Rx Pharmaceuticals, Inc.

156893695

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Lisinopril and Hydrochlorothiazide

Product Details

NDC Product Code
43063-482
Application Number
ANDA077912
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
May 10, 2023
MANNITOLInactive
Code: 3OWL53L36AClass: IACT
ANHYDROUS DIBASIC CALCIUM PHOSPHATEInactive
Code: L11K75P92JClass: IACT
FD&C BLUE NO. 2Inactive
Code: L06K8R7DQKClass: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
STARCH, CORNInactive
Code: O8232NY3SJClass: IACT
ALUMINUM OXIDEInactive
Code: LMI26O6933Class: IACT
Code: E7199S1YWRClass: ACTIBQuantity: 10 mg in 1 1
Code: 0J48LPH2THClass: ACTIBQuantity: 12.5 mg in 1 1
© Copyright 2025. All Rights Reserved by MedPath